SSStephanie Shintani Smith

Stephanie Shintani Smith

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stephanie Shintani Smith has a total of 164 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Biomarker Axes, Detection Limits, and Endotype Stability in CRS: Reply to Katkuri et al. and Hong

    by Asher C. Park, Brooke N. Gleason, Eli Stein, Saied Ghadersohi, Atsushi Kato, Stephanie Shintani‐Smith, David B. Conley, Kevin C. Welch, Robert C. Kern, Bruce K. Tan

  • Open Access

    Appropriate Medical Therapy Primarily Modifies Type 2 and Severity Biomarkers in Chronic Rhinosinusitis

    by Asher C. Park, Brooke N. Gleason, Eli Stein, Saied Ghadersohi, Atsushi Kato, Stephanie Shintani‐Smith, David B. Conley, Kevin C. Welch, Robert C. Kern, Bruce K. Tan

    Background: Appropriate medical therapy (AMT) is first‐line treatment for patients with chronic rhinosinusitis (CRS). We evaluated inflammatory structure, treatment‐induced changes, and biomarker‐outcome associations in AMT‐managed patients. Methods: Fifty‐one CRS patients were evaluated before and after AMT which included a combination of oral antibiotics, oral steroids, or intranasal steroids tailored to CRS phenotype and severity. At each visit, patients completed the SNOT‐22, CRS‐PRO, Brief Smell Identification Test (BSIT), CT scan (Lund–Mackay Score [LM]), and endoscopy (Modified Lund–Kennedy Score [MLK]). Middle‐meatal mucus was analyzed for IL‐1b, IL‐5, IL‐13, IFN‐g, and MIP1a using Luminex and ELISA. Principal components analysis (PCA) was performed on baseline cytokine data to identify key biomarker axes. Paired‐sample Wilcoxon tests compared cytokine changes, and Spearman's correlation assessed relationships between biomarkers and disease measures. Results: PCA revealed two major components: PC‐1 (inflammation severity) dominated by ECP and MIP1a, and PC‐2 (endotype axis) with positive weighting of IL‐5 and IL‐13 (T2) and negative weighting of IFN‐g and IL‐1b (T1/3). AMT significantly reduced inflammatory severity and T2 biomarker burden, driven by decreases in IL‐5, IL‐13, ECP, and MIP1a (all p < 0.01), while T1/3 biomarker remained unchanged. Clinical outcomes, including MLK, SNOT‐22, CRS‐PRO, and BSIT, improved and showed stronger correlations with T2 than T1/3 biomarkers. Conclusion: AMT for CRS is associated with reduction in index biomarkers across inflammatory severity and T2 endotype with minimal effects on T1/3 inflammation. T2‐driven inflammation appears to be the most AMT‐responsive axis found in this study, aligning with measurable improvements in endoscopic, patient reported, and nasal airflow outcomes.


  • The Association Between Sinus Surgery and the Development of Asthma and Non‐Cystic Fibrosis Bronchiectasis in Patients With Chronic Rhinosinusitis

    by Arnaud J. Wautlet, Thanh‐Huyen T. Vu, Ethan Chung, Yasmeen Ali, Nicole Altomare, David B. Conley, Leslie C. Grammer, Atsushi Kato, Robert C. Kern, Robert P. Schleimer, et al.

    Background: Precedent chronic rhinosinusitis (CRS) is associated with new‐onset asthma and non‐cystic fibrosis bronchiectasis (BE). Objective: To assess if endoscopic sinus surgery (ESS) mitigates the development of lower airway diseases in patients with CRS. Methods: This retrospective study utilized electronic medical records from an academic center. CRS patients ( > 18 years old) without asthma or BE, were identified between January 2006 and December 2013. Charts were reviewed until May 2023. New diagnoses of asthma or BE were identified in patient records following ESS before December 2018 compared to patients without ESS. Lund–Mackay (LM) scores were calculated in a random subset of patients to assess disease severity. Logistic regression was used to estimate the odds of developing asthma or BE by ESS status. Results: A total of 1877 patients underwent ESS, while 13,453 did not. CRS severity was higher in the ESS group (LM, 9.02) versus no ESS group (LM, 4.28). After up to 17 years of follow‐up, 207/1877 (11%) and 40/1877 (2.1%) of patients with ESS had a new asthma or BE diagnosis, respectively. Out of 13,453 patients, 1778 (13.2%) and 293 (2.2%) patients without ESS had a new asthma or BE diagnosis. The unadjusted odds of a new asthma diagnosis were lower by 19% for ESS versus no ESS; OR (95% CI), 0.81 (0.70–0.95). After controlling for confounders (age, gender, race/ethnicity, smoking status, and chronic rhinitis), the association remained significant, with a 15% reduction in the odds of a new asthma diagnosis; OR (95% CI), 0.85 (0.73–0.99). There was no association between ESS status and a new diagnosis of BE. Conclusions: Despite higher CRS severity, patients undergoing ESS had a lower risk of a new asthma diagnosis and did not have a higher risk of developing BE.


  • Open Access

    Factor Analysis‐Based Quantitative Endotyping Improves Associations With CRS Cross‐Sectional and Longitudinal Outcomes

    by Brooke N. Gleason, Zhidi Luo, Aditi Agarwal, Siyuan Dong, Regan L. Harmon, Junqin Bai, Chun‐Kang Liao, Julia Huang, David B. Conley, Kevin C. Welch, et al.

    Background: Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disease characterized by persistent sinonasal inflammation. There is increasing interest in endotype‐based classification, which categorizes CRS based on underlying inflammatory pathways. We applied factor analysis to facilitate continuous endotype assignment to CRS patients and assess cross‐sectional and longitudinal CRS outcomes. Methods: We prospectively enrolled 203 patients (52 controls, 88 CRSsNP, and 63 CRSwNP) undergoing endoscopic nasal or sinus surgery (ESS). Middle meatal mucus biomarkers were analyzed pre‐ESS (V0) and 6–12 months post‐ESS (V1). Factor analysis was performed to identify latent factors. Factor scores were generated, and statistical analyses were conducted to assess correlations with radiographic (Lund–Mackay [LM]) and patient‐reported (SNOT‐22, CRS‐PRO) outcomes measured at V0, V1, and V2 (1.5–5 years post‐ESS). Results: Four factors were identified: Type 1 (T1), Type 2 (T2), Type 3 (T3), and macrophage‐associated (M). CRSwNP patients had higher T2 and M factor scores than CRSsNP and controls. T2, T3, and M factor scores demonstrated stronger or equivalent associations with radiographic and patient‐reported outcomes compared to individual biomarkers. Following ESS, median T2 and M factor scores significantly declined, while T1 and T3 remained stable. V0 T1 and T2 were weakly associated with long‐term (V2) radiographic and symptom scores. V1 factor scores were more consistently predictive of long‐term (V2) outcomes, with T2, T3, and M demonstrating modest correlations with radiographic severity and CRS‐PRO. Conclusions: Factor analysis identifies distinct, quantifiable patterns of inflammation in CRS, offering improved associations with cross‐sectional and longitudinal outcomes compared to individual biomarkers.


  • Open Access

    Long‐Term Implications of Short‐Term Symptom and Radiographic Severity Outcomes After ESS in CRS Patients

    by Aditi Agarwal, Zhidi Luo, Siyuan Dong, Caroline P. E. Price, Regan L. Harmon, Junqin Bai, Brooke N. Gleason, David B. Conley, Kevin C. Welch, Stephanie Shintani‐Smith, et al.


  • Top Cited Papers

    Single cell RNA sequencing of human eosinophils from nasal polyps reveals eosinophil heterogeneity in chronic rhinosinusitis tissue

    by Naruhito Iwasaki, Julie A. Poposki, Aiko Oka, Masanori Kidoguchi, Aiko I. Klingler, Lydia A. Suh, Junqin Bai, Whitney W. Stevens, Anju T. Peters, Leslie C. Grammer, et al.


  • Assessing the Quality Improvement Classification System (QICS)

    by Stephanie Shintani Smith

    In this issue of JAMA Otolaryngology–Head & Neck Surgery, Stone et al1 report their development and initial validation of a novel quality improvement classification system, the Quality Improvement Classification System (QICS). Their system was designed to score patient safety events that were being presented at their Quality Assurance Conference (ie, their institution’s morbidity and mortality [M&M] conference). The QICS grades events from level 1 (circumstances of events with capacity to harm the patient but where no harm occurred, ie, near miss) to level 7 (death of a patient). Their goal was to provide a standardized quantification system to analyze and report patient safety events.

  • What's That ODOR? Optimizing the Assessment of Olfactory Dysfunction

    by Stephanie Shintani Smith

    In this issue of JAMA Otolaryngology–Head & Neck Surgery, Lee et al report their development and validation of a novel patient-reported outcome measure (PRO


  • Open Access

    Comparing the severity of chronic rhinosinusitis symptoms before versus during the COVID‐19 pandemic

    by Jasmine S. Lin, Bruce Tan, Chen Yeh, Robert Kern, David Conley, Kevin Welch, Anju Peters, Stephanie Smith

    Background: COVID‐19 measures such as masking, social distancing, and staying indoors may mitigate chronic rhinosinusitis (CRS) symptoms. We evaluate whether these measures correlated with improved symptoms in patients with CRS.Methods: This retrospective study compared SNOT‐22 survey data from the Northwestern CRS Registry at the time of enrollment and at years 1–5 of follow‐up. The final sample consisted of 1826 SNOT‐22 surveys for 598 patients. April 10, 2020 to December 31, 2021 was considered "during the pandemic" and prior to March 11, 2020 was considered "pre‐pandemic." Wilcoxon test was used to compare SNOT22 at enrollment pre‐pandemic versus during pandemic. Separate linear mixed models were performed to estimate SNOT22 at 1 to 5 years after enrollment pre‐pandemic versus during pandemic.Results: Subjects enrolled during the pandemic had worse SNOT22 scores than those enrolled pre‐pandemic (53 vs. 42, p = .0024). Total SNOT‐22 scores were improved during the pandemic than before the pandemic at 1 year follow‐up (18.17 vs. 12.22, p = .001). This effect persists when evaluating the nasal (7.33 vs. 5.13, p = .003), sleep (2.63 vs. 1.39, p = .008), function (1.40 vs. 0.72, p = .015), and emotion (0.77 vs. 0.17, p < .001) domains individually. There was no statistically significant difference in total SNOT‐22 score at Years 2–5 of follow‐up.Conclusions: Patients with CRS experience a greater reduction in symptom severity in their first year of treatment during the pandemic than before the pandemic, plausibly from measures such as masking and staying indoors.Level of Evidence: 4


  • Patient Perspectives on the Drivers and Deterrents of Antibiotic Treatment of Acute Rhinosinusitis: a Qualitative Study

    by Stephanie Shintani Smith, Anne Caliendo, Brian T. Cheng, Robert C. Kern, Jane Holl, Jeffrey A. Linder, Kenzie A. Cameron

    Background Antibiotics are prescribed in >80% of outpatient acute rhinosinusitis (ARS) visits, despite the low incidence of bacterial infection. Previous studies have shown patient expectations are the most robust predictor of antibiotics prescription in ARS. However, patient perceptions are not well known or understood. Objective To understand patient perceptions regarding what drives or deters them from wanting, seeking, and taking antibiotic treatment of ARS. Design Iterative thematic analysis of semi-structured interviews. Participants Nineteen adults diagnosed with ARS within the prior 60 days at the Northwestern Medicine General Internal Medicine clinic in Chicago, IL. Main Measures Perceptions of patients with ARS. Key Results We interviewed 19 patients, identifying the following drivers of antibiotic use: (1) symptoms, especially discolored rhinorrhea, and seeking relief, (2) belief that antibiotics are a convenient and/or effective way to relieve/cure sinusitis, and (3) desire for tangible outcomes of a clinic visit. For deterrents, the following themes emerged: (1) concern about antibiotic resistance, (2) preference for other treatments or preference to avoid medications, and (3) desire to avoid a healthcare visit. Patients identified that a trustworthy physician’s recommendation for antibiotics was a driver, and a recommendation against antibiotics was a deterrent to taking antibiotics; a delayed antibiotic prescription also served as a deterrent. Antibiotic side effects were viewed neutrally by most participants, though they were a deterrent to some. Conclusions Patients have misconceptions about the indications and effectiveness of antibiotics for ARS. Intimate knowledge of key antibiotic drivers and deterrents, from the perspective of patients with ARS, can be leveraged to engage and increase patients’ knowledge, and set appropriate expectations for antibiotics for ARS.